Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy

Area of Science:

• Immunology
• Oncology
• Cancer Biology

Background:

• Malignant cells in lymphomas create pro-tumoral niches that suppress anti-tumor T cell responses.
• The tumor microenvironment (TME) varies across lymphoma types, from inflamed (Hodgkin lymphoma) to non-inflamed (CLL, DLBCL).

Purpose of the Study:

• To review the role of T cells and interferon signaling in regulating anti-tumor immunity and anti-PD-1 therapy sensitivity.
• To explore intrinsic and extrinsic tumor mechanisms affecting immune responses and immunotherapy.
• To incorporate the immunoregulatory function of non-hematopoietic stromal cells within the lymphoma TME.

Main Methods:

• Literature review focusing on TME, immune responses, and immunotherapy in lymphomas.
• Analysis of intrinsic and extrinsic tumor factors.
• Examination of stromal cell contributions to the TME.

Main Results:

• TME characteristics differ significantly among lymphoma subtypes.
• T cells and interferon signaling critically influence anti-tumor immunity and response to checkpoint blockade.
• Non-hematopoietic stromal cells play a significant immunoregulatory role within the TME.

Conclusions:

• Understanding the complex interplay within the immune-stroma lymphoma TME is crucial.
• Targeting TME-driven immune suppression is essential for advancing lymphoma immunotherapies.
• Next-generation immunotherapies and combination strategies are needed to overcome TME-mediated resistance.